Rezultati pretraživanja
  1. part of the fantastic panel of speakers and organizers “Facts and hopes”. Madrid

  2. 23. stu 2019.

    Other directions for anti-Siglec-15 mAbs. Bone metastases?

  3. Following our simposium Facts and hopes The ITN consortium on Tumor Treg targeting coordinated by Dr. Melero met this morning at Clinica Universidad de Navarra in Madrid

  4. Glad to be with all our ITN ESRs in Madrid

  5. 23. stu 2019.

    Happy and honored to speak at Its been a pleasure to be and talk to the most relevant researchers in immunotherapy such as , Dr. Lorenzo Moretta from , and Ignacio Melero from . Hope to see you next year

  6. 22. stu 2019.

    Tx to Dr Melero for invitation & honored to speak at hosted Great to see friends & luminaries such as Dr Lorenzo Moretta’s seminal work on NK cells. Love talking DCs, type I IFN, checkpoint blockade, , & more!

  7. 24. stu 2019.

    I enjoyed your presentation and data at . Could increased HIF activity (mutant VHL) drive T cell infiltration in tumors?

  8. 4. pro 2018.

    Un placer compartir conocimiento con expertos internacionales de la talla de Ignacio Melero, Antoni Ribas, Kurt Schalper, Solange Peters, o Luca Mazzarella ayer en el

  9. 30. stu 2018.
    Odgovor korisnicima i sljedećem broju korisnika:

    It's an honor and a privilege to be part of this

  10. Unos ponentes y un programa espectacular para conocer cómo la inmunoterapia está cambiando el tratamiento del cáncer

  11. 23. stu 2019.

    tour-de-force by Pablo Umaña innovation center Zurich on next gen antibodies against tumor and T cell markers to improve

  12. 23. stu 2019.

    Great talk by explaining molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed across types

  13. 2. pro 2018.
    Ovo je potencijalno osjetljiv multimedijski sadržaj. Saznajte više
  14. 23. stu 2019.

    Fantastic talk by on the role of antagonistic profiles in immunity based on a COX-associated signature

  15. 👨‍🔬Según nuestro científico, “los mayores éxitos hoy por hoy se están consiguiendo combinando inmunoterapia con estrategias convencionales”

  16. 24. stu 2019.
  17. 24. stu 2019.

    Necesitamos investigación para seguir vivas... Y muchas que pueden venir detrás necesitan investigación para lo mismo. La mejor y casi única opción pasa por dotar de fondos a los investigadores.

  18. "Ha sido un placer poder traer a la audiencia española los últimos avances en del cáncer. Este simposio internacional es una apuesta por la enseñanza y alianzas en investigación que repetiremos el próximo año" El Dr. Ignacio Melero clausura

    Prikaži ovu nit

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.